Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut.
In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care. Included are academics, CEOs of small and mid-sized companies, and rising employees in larger biopharma and medtech businesses.
There is no age restriction to being included, but all those named below have been recognized for bringing something new...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
